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Song-Gun Kim‡, Nathan P. Manes§, M. Raafat El-Maghrabi§, and Yong-Hwan Lee‡1
From the ‡Department of Biological Sciences, Louisiana State University, Baton Rouge, Louisiana 70803 and the §Department of
Physiology and Biophysics, State University of New York at Stony Brook, Stony Brook, New York 11794-8661
The hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) plays a crucial role in the progression of cancerous cells by enabling their glycolytic pathways
even under severe hypoxic conditions. To understand its structural
architecture and to provide a molecular scaffold for the design of
new cancer therapeutics, the crystal structure of the human form
was determined. The structure at 2.1 Å resolution shows that the
overall folding and functional dimerization are very similar to those
of the liver (PFKFB1) and testis (PFKFB4) forms, as expected from
sequence homology. However, in this structure, the N-terminal regulatory domain is revealed for the first time among the PFKFB isoforms. With a ␤-hairpin structure, the N terminus interacts with the
2-Pase domain to secure binding of fructose-6-phosphate to the
active pocket, slowing down the release of fructose-6-phosphate
from the phosphoenzyme intermediate product complex. The
C-terminal regulatory domain is mostly disordered, leaving the
active pocket of the fructose-2,6-bisphosphatase domain wide open.
The active pocket of the 6-phosphofructo-2-kinase domain has a
more rigid conformation, allowing independent bindings of substrates, fructose-6-phosphate and ATP, with higher affinities than
other isoforms. Intriguingly, the structure shows an EDTA molecule bound to the fructose-6-phosphate site of the 6-phosphofructo-2-kinase active pocket despite its unfavorable liganding concentration, suggesting a high affinity. EDTA is not removable from
the site with fructose-6-P alone but is with both ATP and fructose6-P or with fructose-2,6-bisphosphate. This finding suggests that a
molecule in which EDTA is covalently linked to ADP is a good starting molecule for the development of new cancer-therapeutic
molecules.

Mammalian tissues have evolved to carry out various functions under
different physiological conditions. Such differentiation has naturally
caused the tissue cells to have different optima for their energy metabolism. The bifunctional enzyme, 6-phosphofructo-2-kinase/fructose2,6-bisphosphatase (PFKFB,2 2-Kase/2-Pase), plays a key role in such
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tissue-specific energy metabolism by controlling glucose utilization.
Because this enzyme controls the cellular concentration of fructose-2,6bisphosphate (Fru-2,6-P2), which is the most potent allosteric activator
of phosphofructokinase, the rate-limiting enzyme of glycolysis, PFKFB
eventually controls the glycolytic rate (1–3). The bifunctional enzyme
acutely controls the concentration of Fru-2,6-P2 by modulating the two
mutually exclusive catalytic activities of Fru-2,6-P2 synthesis (2-Kase)
and hydrolysis (2-Pase) that reside in the two separate domains (4, 5).
The two activities are exquisitely regulated by various metabolic products and signal transduction-dependent phosphorylation such that the
resulting predominant activity determines the final concentration of
Fru-2,6-P2 and, ultimately, the rates of glycolysis (6 –9).
To optimize glucose utilization for physiological roles, every mammalian cell is equipped with one of four PFKFB isoforms, the liver, heart,
testis, and inducible forms that are encoded by distinct genes (10 –14).
Although these isoforms share high “2-Kase/2-Pase core” sequence
homology (85%), each isoform has different kinetic properties and
responds differently to upstream regulatory signals. This is a function of
the highly divergent N- and C-terminal regulatory domains and the
sequence differences in the second shell residues surrounding the active
sites of the catalytic domains (11). Unlike the other tissue-specific isoforms, the inducible form is ubiquitously expressed by hypoxic stress
(10, 15) and found to be identical to the forms previously isolated from
placenta (16), pancreatic ␤-islet (11), or brain (17). The inducible form
has an uncharacteristically high and predominant 2-Kase activity with a
2-Kase/2-Pase activity ratio larger than 700 (18, 19). This is contrast to
the much lower ratios of the liver, testis, and heart forms of 1.5, 4, and
80, respectively (1, 11). Phosphorylation of the inducible form on Ser460 by PKA, or AMP-dependent protein kinase, increases the ratio to
⬎3000 (8, 19 –22).
Recent studies show that the inducible form is also frequently found
in cancer cells (10, 22, 23). Proliferating cancer cells, which have a higher
dependence on glucose for their metabolic needs, obtain ATP from
glycolysis rather than by oxidative phosphorylation even under aerobic
conditions and, thus, show a much higher rate of glycolysis than normal
cells (24). In addition, the severe hypoxic stress under which the cancer
cells proliferate inside the mass allows no other energy metabolic pathway but glycolysis. Metabolic adaptation to hypoxia is initiated by
changes in gene expression patterns triggered by anaerobic activation of
hypoxia-inducible factor 1 (HIF-1), and the gene (pfkfb3) for the inducible bifunctional enzyme is one of the most immediate targets of transcriptional activation by HIF-1 (15, 25–27). The extremely high 2-Kase
activity of the inducible PFKFB provides the impetus for vigorous glytase; 2-Kase, 6-phosphofructo-2-kinase; 2-Pase, fructose-2,6-bisphophatase; Fru-6-P, fructose-6-phosphate; Fru-2,6-P2, fructose-2,6-bisphophate; E-P, phosphoenzyme
intermediate.

JOURNAL OF BIOLOGICAL CHEMISTRY

2939

Crystal Structure of PFKFB3
colysis in cancer cells. Recent studies suggest that inhibition of glycolysis
to deplete the cellular ATP may serve as an alternative strategy to kill
cancer cells that have acquired resistance to traditional drugs. Thus, the
inducible PFKFB has been considered as the primary target (26, 28).
We have studied the PFKFB enzyme system for several years and have
made significant contributions to understanding the structure/function
relationships of the enzyme at a molecular level (29 –31). To understand
molecular differentiation of the entire PFKFB protein system, which has
been the long-term goal of our study, and to provide information on the
molecular structure of possible therapeutic targets for cancer, we report
here the crystal structure of the human tumor/inducible form of
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3).

TABLE 1
Statistics of reflection data and structure refinements
Rsym ⫽ 兺h(兺j兩Ih,j ⫺ 具Ih典兩/兺Ih,j), where h is a set of Miller indices, j is a set of observations of reflection h, and 具Ih典 is the mean intensity. Root mean square deviation
(r.m.s.d.) values are deviations from ideal values. Rcrys ⫽ 兺h储Fo,h兩 ⫺ 兩Fc,h储/兺h兩Fo,h兩.
Rfree was calculated using 10% of the complete data set excluded from refinement.
The numbers in parentheses represent values from the last shell.
Liganding

PFKFB3䡠ADP䡠EDTA

Unit cell dimension (Å)

PFKFB3䡠ADP䡠Fru-2,6-P2

P6522

Space group

102.6 ⫻ 102.6 ⫻ 259.9
30.0–2.1

Resolution range (Å)
Reflections 关F >  (F )兴
Completeness (%)
Redundancy

P6522
102.2 ⫻ 102.2 ⫻ 259.2
30.0–2.5

44,651

28,580

92.8 (87.6)

99.7 (97.8)

9.6 (9.3)

13.9 (9.2)

16.9 (1.5)

15.3 (1.9)

MATERIALS AND METHODS

I/(I)

Preparation and Crystallization of PFKFB3—The His-tagged human
inducible bifunctional enzyme was expressed in Escherichia coli
BL21(DE3) pLysS and purified using nickel-affinity columns, and the
N-terminal His tag was removed by treatment with thrombin using a
standard protocol (19). The final purification was performed using
Mono Q anion-exchange chromatography; the resulting pure protein
was kept, after concentration to 8 mg ml⫺1 protein, in pH 8.0, 20 mM
Tris-HCl, 10 mM NaPi, 0.05 mM EDTA, 5 mM ␤-mercaptoethanol, 0.2
mM ADP, 5% glycerol, and 0.2 mM Fru-6-P. Crystals were prepared by
the sitting drop vapor diffusion of the 1:1 mixture of the protein sample
with a mother liquor of 50 mM Tris-HCl, pH 7.5, 20 –25% ethylene
glycol, 12% dioxane, 5% glycerol, and 12% polyethylene glycol 4000.
Crystals in a size of 0.2 ⫻ 0.2 ⫻ 0.05 mm were grown in 2–3 weeks.
Data Collection and Processing—The crystal was soaked with cryoprotectant solutions for 0.5–2 h to remove inorganic phosphate and to
incorporate the targeted ligands. A typical cryoprotectant solution is pH
7.5, 20 mM Tris-HCl buffer enriched with 35% ethylene glycol and 1.0
mM Fru-2,6-P2. A soaked crystal was flash frozen at 100 K using an
Oxford cryo-device and kept at the same temperature during data collections. The diffraction data were collected at The Gulf Coast Consortium Protein Crystallography PX1 beamline in The Center for
Advanced Microstructures and Devices, Louisiana State University
(Baton Rouge, LA). The x-ray source wavelength was 1.3808 Å. The data
recorded on a Mar 165-mm CCD detector were integrated, merged, and
scaled using HKL2000 (32), and the resulting data statistics are summarized in Table 1.
As summarized in Table 1, the crystals belong to space group P6522
with similar cell dimensions regardless of the liganding conditions. The
reduced data were formatted for the program suites CCP4 (33) and CNS
(34), and 10% of the data were marked for free R-factor measurements in
subsequent structure refinements.
Structure Determination and Refinement—The structure of PFKFB3
complexed with ADP and EDTA was determined first by molecular
replacement using AMoRE (35) implemented in the CCP4 suite (33). A
single polyalanine form of the liver structure (Protein Data Bank accession code 1K6M) (31) was used as a search model. An AMoRE rotation
and subsequent translation search was performed using a data subset
between 15.0 and 4.0 Å. The molecular replacement search as well as the
measurement of solvent fraction suggested a single protein molecule in
an asymmetric unit. A good molecular replacement solution was found
to show an R-factor of 0.52 and a correlation factor of 0.58. Assignment
of the side chains was made using program O (36). The initial model
went through iterated cycles of manual model rebuilding using O program and refinement at 2.1 Å using CNS (34). When Rcrys/Rfree reached
0.27/0.29 or below, the ligand molecules were built into the model,
referring to the 兩Fo兩 ⫺ 兩Fc兩 omit maps. ADP and the 2-Pase-bound Fru-

Rsym

0.107 (0.687)

0.099 (0.535)

Rcrys

0.209

0.214

Rfree

0.233
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No. of protein atoms

0.262

452

449

3,669

3,658

No. of amino acids
No. of hetero atoms
No. of waters

63

66

353

221

R.m.s.d. bond lengths (Å)
Angles (°)
Dihedral angles (°)

0.010
1.6
22.6

0.006
1.3
22.2

Mean B factor
Protein atoms (Å2)
Hetero atoms (Å2)
Water atoms (Å2)

34.42
31.81
46.7

43.6
41.1
52.3

6-P were incorporated first, and EDTA was added after mass spectrometric confirmation of the crystal. As summarized in Table 1, the final
model has Rfree/Rcrys of 0.233/0.209 using a total of 4,085 scatterers,
including solvent molecules, against all available 44,651 reflections in
the resolution range of 30.0 –2.1 Å. The structure contains a total of 452
protein residues of the full-length protein of 520 residues.
The subsequent structure of PFKFB3 complexed with ADP and Fru2,6-P2 was determined by using the structure of the protein䡠ADP䡠EDTA
complex after striping the ligands and solvents as the initial model and
by following the structural refinements procedures similar to that used
for the structure of the protein䡠ADP䡠EDTA complex. But to guarantee a
freedom to structural refinements, the indices of reflections in the free
data were kept as those of the protein䡠ADP䡠EDTA complex. The final
structure has Rfree/Rcrys of 0.262/0.214 using a total of 3,945 scatterers,
including solvent molecules, against all available 28,580 reflections in
the resolution range of 30.0 –2.5 Å. The structure contains a total of 449
protein residues of the full-length protein of 520 residues. The refinement statistics are summarized in Table 1.

RESULTS AND DISCUSSION
Overall Structure—The PFKFB3 protein was crystallized under conditions similar to those for the liver form (31). The structures from the
two different liganding conditions were determined by molecular
replacement using the liver structure as a start model. The two different
liganding conditions used were ADP and fructose-6-phosphate (Fru6-P) and ADP and Fru-2,6-P2, and the resulting resolutions of the final
structures were 2.1 and 2.5 Å, respectively. Among all the structureassigned residues, 89% are in the most favored regions in a Ramachandran plot, 9.5% in the additional allowed region, and the rest in the
generously allowed region. Details of the crystallographic statistics are
summarized in Table 1. Most descriptions of the structure below are
according to the structure determined to 2.1 Å resolution, unless spe-
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FIGURE 1. Overall folding of PFKFB3 and the N terminus. A, a ribbon diagram of the
dimeric PFKFB3 structure is shown with the bound ligands. One protein subunit is light
colored for convenient comparison. ADP are bound to the 2-Kase (magenta) active
pocket and Fru-6-P to the 2-Pase (blue). The N-terminal regulatory domain is shown in
green. B, The 2 Fo ⫺ Fc electron density maps are contoured around the N-terminal
hairpin structure at 1.1  levels. The structure is from the final model. C, a stereo view of
the interactions between the N terminus (green) and the 2-Pase domain (gray). The
involved hydrogen bonds and salt bridges are shown as broken lines. Unless specifically
mentioned, all structural figures were made using MolScript v2.1.2 (45) and rendered
using Raster3D v2.7 (46). The electron density maps are drawn using BobScript v1.4b.

cifically mentioned. Amino acid sequence numbers are from the inducible PFKFB3. When the sequence is different in other isoforms, the
different sequence is given in a small case. For example, S162e means the
162nd residue in the inducible protein is Ser and the equivalent residue
in the liver form is Glu.
As predicted from the high sequence homology (85%) between the
PFKFB isoforms, the folding of the inducible form is very similar to
those of the testis and liver forms (31, 37). As shown in Fig. 1a, a PFKFBtypical head-to-head functional dimerization is also conserved.
However, the inducible form also has structural features uniquely
different from the other isoforms. The conformations of the substrate

FEBRUARY 3, 2006 • VOLUME 281 • NUMBER 5

loops in the 2-Kase domain are different from those of other isoforms
(31, 37), providing a structural rationale for the higher 2-Kase activity.
The structure of the N-terminal regulatory domain is revealed: the N
terminus binds to the 2-Pase domain to cause a local conformational
change in the active pocket to enhance inhibitory binding of product.
Most strikingly, an EDTA molecule was found at the Fru-6-P site of the
active pocket of 2-Kase. Detailed descriptions of these structural features of the inducible form will be made in following sections.
Autoregulation of the 2-Pase by the N-terminal Domain—This is the
first time the structure of the regulatory N terminus (residues 2–28 of 31
residues) has been revealed among any of the solved PFKFB structures.
As shown in Fig. 1, a and b, residues 4 –15 form a ␤-hairpin structure,
and the rest serve as an arm connecting the hairpin to the 2-Kase. The
turn of this hairpin makes a contact with its own 2-Pase domain and
causes a global rotation of the 2-Pase domain from its relative position in
the liver form (data not shown). Although the domain twist is interesting, its functional effect is not clear.
On the other hand, the contacting area of the 2-Pase domain is functionally very sensitive because the residues critical for binding of both
product and substrate are located in close proximity (Fig. 1c). The three
key residues, Arg-347, Lys-351, and Tyr-362, which interact with the
6-phosphate moiety (6-P) of substrate (Fru-2,6-P2) and product (Fru6-P) are located in this area (38, 39). Binding of the N terminus to this
area is mediated by salt bridges and/or hydrogen bonds between Arg-8
and Glu-342, between the main chain of Val-9 and that of Tyr-354,
between Gln-10 and Gln-363 and Arg-355, and between Lys-11 and the
main chain of Arg-355. As a result, the ␤-strand where Tyr-354, Arg355, and Tyr-356 are located moves deep inside by more than 1 Å; as a
result, a local network of side chain interactions is reorganized when
compared with that of the liver form. Tyr-354 makes a hydrogen bond
to Glu-343 and Tyr-356 to Arg-347. Consequently, the interaction of
Arg-347 with 6-P of the bound Fru-6-P becomes stronger with a distance shortened by 0.7 Å. Similarly, the distances from 6-P to Lys-356
and Tyr-362 are shortened by 0.7 and 0.4 Å, respectively. This may cause
a substantial increase in affinities for both substrate and product.
Because of sequence difference from other isoforms, the inducible
form has a serine instead of an arginine at the 302nd residue. The corresponding Arg-307 in the liver form and all other isoforms has dual
functions by providing a positive charge for the 2-phosphate moiety
(2-P) of substrate: facilitating substrate binding and stabilizing the phosphoenzyme intermediate (E-P) during its breakdown (40). Thus, the
inducible PFKFB is doubly compromised by the loss of arginine at this
position; its affinity for substrate is decreased, and the rate of E-P breakdown is drastically slowed. Yet, binding of the product, Fru-6-P, which is
a potent non-competitive inhibitor of the reaction, is not affected. Sitespecific mutagenesis of the liver 2-Pase showed similar results, and the
current structure supports the observation (40). Thus, the net result of
the loss of arginine in the inducible PFKFB is that its 2-Pase reaction
spends more time in the E-P䡠Fru-6-P complex state. This was kinetically
observed in a recent study in which the arginine residue was restored
(19). In addition, the interaction with the N terminus mentioned above
confers an even tighter binding of Fru-6-P, reducing the activity of the
inducible form to negligible rates. Consequently, the N terminus exerts
a negative regulatory effect on the 2-Pase activity by enhancing the
binding of inhibitor, Fru-6-P, or, more precisely, by slowing down the
catalytic rate-limiting step, the release of Fru-6-P from the E-P䡠Fru-6-P
complex. Supporting this hypothesis, the alternative mRNA splicing
product of the inducible PFKFB, in which the N terminus is naturally
deleted, has a 7-fold higher 2-Pase activity (19).

JOURNAL OF BIOLOGICAL CHEMISTRY

2941

Crystal Structure of PFKFB3

FIGURE 2. Differentiation of the substrate loops and the contribution from the
2-Pase domain. A, the structures of the 2-Kase substrate loops are compared. The ATP
and Fru-6-P loops are distinguished from each other by the labels and the bound ADP
and EDTA. To compare the conformational differences, the liver structure is also superimposed in gray. B, the interaction between Tyr-424 and ADP is shown. The 2-Kase
domain is in magenta and the 2-Pase in light blue.

Substrate Binding Loops of the 2-Kase Domain—The 2-Kase domain
has binding sites for the two substrates, ATP and Fru-6-P, the binding of
which are sensitive to the conformations of the two outer lobes known
as the ATP loop (residues 168 –179) and the Fru-6-P loop (residues
72– 84) that surround the whole active pocket (31, 41). In the testis
form, the two loops are structurally coupled to each other through two
hydrogen bonds donated by Arg-181. Upon binding of ATP, the last
turn of helix ␣5 unwinds to allow Lys-172 to interact with ␥-phosphate.
This conformational change is transmitted to the Fru-6-P loop via Arg181 such that the Fru-6-P loop has a new conformation. Fru-6-P can
bind only to this new conformation (41). Thus, binding of Fru-6-P is
dependent on that of ATP in the testis form in an ordered fashion.
However, the native liver form with a cysteine instead of an arginine has
the two loops decoupled from each other. As a result, their conformations are different from those in the testis form, and the two substrates
bind independently from each other (31).
The inducible form also has a cysteine instead of an arginine, and thus
the two loops are decoupled like in the liver form, allowing the independent binding of substrate. In addition, as shown in Fig. 2a, sequence
differences in the residues of N178d and E181k provide new interactions necessary to form an additional helix turn to the end of the ATP
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FIGURE 3. Interactions between the 2-Kase and the bound ligands. A, the presences
of EDTA and Fru-2,6-P2 are shown from the omit maps. The Fo ⫺ Fc electron density
maps are contoured at 2.5  levels, and the ligand structures are from the final models.
The map of EDTA is shown at the top and that of Fru-2,6-P2 at the bottom. B, the interactions between EDTA and the 2-Kase active site residues are shown. To show its relative
position, ADP is also shown. C, the interactions between Fru-2,6-P2 and the 2-Kase active
site residues are shown. For comparisons of positions of the bound EDTA and Fru-2,6-P2,
the view points were kept similarly.

loop. The substitution of Gln-80 with serine and an added Lys-79
change the local conformation of the Fru-6-P loop to a helix turn; as a
result, Tyr-81 makes a hydrogen bond to the main body of the following
helix through Asp-185.
The sequence differences in these loop regions add helix turns to the
two substrate loops, decreasing the conformational flexibilities of these
loops compared with the coil structures of the other forms. The
restricted conformations of the two loops appear to enhance binding of
substrates.
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TABLE 2
Interactions between the protein and the Fru-6-P site-bound ligands
EDTA

Protein
Lys-47
Arg-74
Arg-75
Arg-98
Thr-126

Ligand
NZ
NE
NH2
NH1
NH2
NH2
OG1
N

O5
O4
O2
O7
O8
O4
O3
O6

Distance (Å)
2.8
2.6
2.7
3.1
3.0
3.2
3.2
2.9

ATP Binding and the 2-Pase—As shown in Fig. 2b, because of the
sequence differences of S162e and M165r from the liver form, the solvent-exposed ␣5 moves downward and eventually creates a hydrogen
bond between Glu-166 and Ala-423, which does not exist in other isoforms. Consequently, the conformation of the unwound last turn of ␣5
is kept stable and pulls a ␤-hairpin (residues 415– 432) from the 2-Pase
domain toward ␣5. The hairpin has Tyr-424, which is the only residue
from the 2-Pase domain directly involved in the 2-Kase reaction by
interacting with ATP. With help from the water-mediated hydrogen
bond between Lys-52 and Glu-72, which intercalates the phenyl ring of
Tyr-424 between Lys-52 and Val-167, the interaction between Tyr-424
and the bound ADP is firmer with the distance shortened by 0.5 Å. This
may increase the affinity of the 2-Kase for ATP.
As described above, the different amino acid sequences introduced
into the inducible form contribute to the conformations of the two
substrate loops and the other structural elements required for substrate
bindings. Together, they provide a structural basis for better affinities
for substrates and, ultimately, the highest 2-Kase activity among the
PFKFB isoforms.
Binding of EDTA to the Fru-6-P Site of 2-Kase—Despite continuous
efforts for the last several years, structural characterization of the Fru6-P site in the 2-Kase active pocket has never been successful. Structural
information on this site is very important for understanding of the catalytic mechanism carried out by the 2-Kase of all PFKFB isoforms. As a
trial to define the site, the crystals of the inducible form PFKFB were
soaked with a cryoprotectant containing 0.2 mM Fru-6-P before data
collection. When the兩Fo兩 ⫺ 兩Fc兩 omit map was generated (Fig. 3a, top),
the putative Fru-6-P site was found to be occupied by an EDTA molecule. It was surprising because the Fru-6-P concentration was 3-fold
higher than that of EDTA and because EDTA has never been reported
to compete with Fru-6-P for the 2-Kase. Moreover, almost all experimental conditions for the 2-Kase activity assay to date have at least 0.05
mM EDTA, the same concentration that we used. These circumstances
cultivated suspicion about the functional nature of this site. To clear the
ambiguity, the structures from the crystals soaked with different liganding conditions were determined. From those experiments, it has been
found that EDTA is not displaceable from the site with Fru-6-P alone
but is with both ATP and Fru-6-P or with Fru-2,6-P2. Among those,
soaking with 0.5 mM Fru-2,6-P2, a product of the 2-Kase reaction, was
least damaging to the crystals, and thus the resulting structure is also
introduced in this report. The omit map from the Fru-2,6-P2-soaked
crystal is shown in the bottom of Fig. 3a.
As compared in Fig. 3a, the two omit maps are clearly different and
suggest two different molecules. Binding of EDTA and Fru-2,6-P2 were
subsequently confirmed by mass spectrometric analysis of the soaked
crystals (data not shown). When the final structures were compared
(Fig. 2, b and c), it was found that Arg-74, Arg-98, and Thr-126 are
commonly employed for binding of the two different molecules. As
compared in the figures, the two molecules occupy nearly the same
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Fru-2,6-P2

Protein
Arg-74
Arg-98
Arg-132
Arg-189
Thr-126
Tyr-193

Ligand
NH2
NH2
NH1
NE
OG1
N
OH

O2P
O4P
O5P
O1
O6P
O6
O4P

Distance (Å)
2.7
3.1
2.7
2.9
2.6
3.1
2.6

place, a pocket right next to the ADP site. Finally, it was concluded that
EDTA binds to the Fru-6-P site. Interactions between the protein residues and the two ligands are summarized in Table 2.
As shown in Fig. 3b and summarized in Table 2, seven of eight oxygen
atoms in EDTA are recruited for salt bridges or hydrogen bonds to the
protein residues, which are all positively charged except for Thr-126. To
accommodate these interactions with protein, EDTA has an extended
conformation. As indicated by the interaction distances in Table 2, the
interactions between EDTA and protein are very tight, explaining the
unexpectedly high affinity of EDTA. As shown in Fig. 3, ADP is located
right next to EDTA with an approximate distance of 3 Å, which is
shorter than two average covalent bonds. This proximity suggests a
molecular scaffold of the potential inhibitors for the 2-Kase activity of
the inducible bifunctional enzyme. As mentioned in the Introduction,
the inducible PFKFB is one of the major driving force molecules responsible for tumorigenesis. Suppression of vigorous glycolysis, a hallmark of
oncogenic cells, has been suggested as an effective alternative to traditional cancer therapies, and genetic disruption of the inducible PFKFB
has been observed to induce deaths of cancerous cells (10, 22, 26, 28).
Therefore, an efficient inhibitor for the 2-Kase activity of the inducible
PFKFB can serve as a new therapeutic molecule for cancer. Based on the
current structure, we suggest a scaffold of the inhibitor new synthetic
molecules to be a conjugate molecule in which one acyl group of EDTA
is covalently linked to ␤-phosphate of ADP.
Biological Significance—Among the four PFKFB isoforms, only the
structures of the liver and testis forms have been solved (31, 37), and
with the results presented here, the inducible form may be added to the
list. The previous structural studies have made great contributions
toward understanding of the PFKFB protein at the molecular level.
Nonetheless, catalytic mechanism of their 2-Kinase reaction is not very
well understood, because structural characterization of the Fru-6-P
pocket has never been successful. In this report, we provided information on the interactions between the protein and Fru-6-P. To provide
long-waited information on the 2-Kinase reaction, a subsequent structure/function study is being made.
Finding of the N terminus is particularly significant because it seems
to exert self inhibition on the 2-Pase, which is more distantly located
than the 2-Kase. The previous functional studies of the liver enzyme
have suggested that the N terminus may interact with the neighboring
2-Kase domain to enhance Fru-6-P binding (42). Based on this observation, it was expected that the N terminus of PFKFB3 might also be
located near the 2-Kase domain. However, the sequences for the hairpin
structure (residues 4 –15) appear to be well conserved among the inducible, liver, and testis forms, suggesting that N-terminal sequences of the
liver and testis forms may also form hairpin structures to exert their
regulatory effects. This is consistent with early kinetic data on enhanced
2-Pase activity observed with N-terminal phosphorylation (43). However, because the residues connecting the hairpin to the 2-Kinase
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domains are highly divergent among the isoforms, it is unpredictable
where their N termini would bind.
Together with our previous structural studies (31), the current study
suggests that a small number of sequence variations in the catalytic
domains cause differences in the substrate loop interactions and that
the variable N- and C-terminal regulatory domains function as intrinsic
inhibitors of the catalytic domains. Combination of these allows the four
tissue isoforms of PFKFB to have different kinetic properties and regulatory mechanisms. Putting aside the C-terminal domains, which either
are disordered (the inducible form) or cover the 2-Pase active pocket
(the liver and testis forms), the varied loop interactions and/or the N
terminus produce differing binding affinities and release rates of substrates or products during the catalytic steps. Mechanistically, these
functional effects are made by strengthening or weakening the interactions between the key residues and substrates/products. To achieve this,
they affect the secondary shell residues, which are located next to the
key residues to determine electrochemical environments of the catalytic
reactions.
Compared with alterations in the primary components such as constellations of catalytic residues that can easily cause orders of magnitude
differences in kinetic properties (44), variations in the secondary components are more suitable for modest kinetic differences in a range of 2to 20-fold, which is comparable with the differences between the PFKFB
isoforms, and thus are employed as a central scheme of the molecular
evolution of the four isoforms of PFKFB.
Binding of EDTA to PFKFB3 raises a possibility that EDTA might
have induced a non-physiological conformation of PFKFB3. The suspicion could be ruled out by two observations. First, PFKFB3 can be crystallized without EDTA. Second, when the crystal was soaked with ATP
and Fru-6-P, Fru-2,6-P2 was synthesized and found in the structure
(data not shown), indicating that the conformation in the presence of
EDTA is suitable for the physiological function of PFKFB3.
The inducible PFKFB is one of the major metabolic effectors that
facilitate cancer progression. Suppression of glycolysis has been frequently suggested as an effective alternative to traditional cancer therapies; accordingly, the inducible PFKFB has been considered as one of
the primary targets of such approaches. The discovery of EDTA at the
Fru-6-P site provides a molecular paradigm of a new therapeutic molecule that targets the 2-Kase activity of the inducible PFKFB for cancer
treatments. A suggested starter molecule resembles EDTA covalently
linked to the ␤-phosphate of ADP.
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